Concert Pharma

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Concert Pharmaceuticals is a clinical-stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with the potential for efficacy and safety, while greatly reducing R&D risk, time, and expense.

Alpine Immune Sciences

Everspin Technologies

ShiftPixy

SG Blocks

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

AI Models Say These Are The Best Stocks To Short Today

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Concert (CNCE) Upgraded to Buy: Here's Why

Is  (CNCE) Outperforming Other Medical Stocks This Year?

Is Concert Pharmaceuticals (CNCE) Stock Outpacing Its Medical Peers This Year?

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) fell by 1.8% from the previous closing price.

Insider Sells Concert Pharmaceuticals' Shares

Avenue Therapeutics

MEI Pharma

Minerva Neurosciences

Ocular Therapeutix

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Concert Pharmaceuticals (CNCE) Stock Stands Out in a Strong Industry

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2020 Results - Earnings Call Transcript

Concert (CNCE) Moves to Buy: Rationale Behind the Upgrade

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2019 Results - Earnings Call Transcript

Concert Pharmaceuticals, Inc (CNCE) CEO Roger Tung on Q3 2019 Results - Earnings Call Transcript

Shares fall hard after a late-stage trial comes up short.

Why Concert Pharmaceuticals Stock Is Tanking Today

Concert announced that it had achieved the primary endpoint in the phase 2 study using CTP-543 to treat patients with alopecia areata.

Concert Gears Up For Late-Stage Study After Showing It Has The Goods For Treating Hair Loss

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2019 Results - Earnings Call Transcript

Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.

Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I

Shares at one point tripled shortly after my original article but have lost around half their value since my last update piece.

Concert Pharmaceuticals: Cheap Valuation With Multiple Programs Moving Forward

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2019 Results - Earnings Call Transcript

There is an old drug that might have lots of new tricks in its sleeve.

Concert And Processa: Pentoxifylline Reborn

Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.

Concert Pharma Initiates Early-Stage Schizophrenia Study

Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its alopecia areata treatment CTP-543 were "not patentable.

News for Concert Pharma Stock (CNCE)